| ［1］ |
Bray F， Laversanne M， Sung H， et al. Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin， 2024， 74（3）: 229-263.
|
| ［2］ |
Han B， Zheng R， Zeng H， et al. Cancer incidence and mortality in China， 2022［J］. J Natl Cancer Cent， 2024， 4（1）: 47-53.
|
| ［3］ |
Koppe MJ， Boerman OC， Oyen WJ， et al. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies［J］. Ann Surg， 2006， 243（2）: 212-222.
|
| ［4］ |
Klaver YL， Lemmens VE， Nienhuijs SW， et al. Peritoneal carcinomatosis of colorectal origin: incidence， prognosis and treatment options［J］. World J Gastroenterol， 2012， 18（39）: 5489-5494.
|
| ［5］ |
Franko J， Shi Q， Goldman CD， et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841［J］. J Clin Oncol， 2012， 30（3）: 263-267.
|
| ［6］ |
Foster JM， Zhang C， Rehman S， et al. The contemporary management of peritoneal metastasis: a journey from the cold past of treatment futility to a warm present and a bright future［J］. CA Cancer J Clin，2023，73（1）: 49-71.
|
| ［7］ |
Lemmens VE， Klaver YL， Verwaal VJ， et al. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study［J］. Int J Cancer， 2011， 128（11）: 2717-2725.
|
| ［8］ |
Balshem H， Helfand M， Schünemann HJ， et al. GRADE guidelines: 3.Rating the quality of evidence［J］. J Clin Epidemiol， 2011， 64（4）: 401-406.
|
| ［9］ |
Paget S. The distribution of secondary growths in cancer of the breast.1889［J］. Cancer Metastasis Rev， 1989， 8（2）: 98-101.
|
| ［10］ |
Pietrasik JM， Uruski P， Tykarski A， et al. The peritoneal “soil” for a cancerous “seed”: a comprehensive review of the pathogenesis of intraperitoneal cancer metastases［J］. Cell Mol Life Sci， 2018， 75（3）:509-525.
|
| ［11］ |
Kim SJ， Kim HH， Kim YH， et al. Peritoneal metastasis: detection with 16- or 64-detector row CT in patients undergoing surgery for gastric cancer［J］. Radiology， 2009， 253（2）: 407-415.
|
| ［12］ |
Dong D， Tang L， Li ZY， et al. Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer［J］. Ann Oncol， 2019， 30（3）: 431-438.
|
| ［13］ |
Koh JL， Yan TD， Glenn D， et al. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis［J］. Ann Surg Oncol， 2009， 16（2）: 327-333.
|
| ［14］ |
Wang J， Hu Y， Xiong H， et al. CT-based deep learning model: a novel approach to the preoperative staging in patients with peritoneal metastasis［J］. Clin Exp Metastasis， 2023， 40（6）: 493-504.
|
| ［15］ |
Dromain C， Leboulleux S， Auperin A， et al. Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT［J］. Abdom Imaging， 2008，33（1）: 87-93.
|
| ［16］ |
Yamada A， Oguchi K， Fukushima M， et al. Evaluation of 2-deoxy-2-［18F］fluoro-D-glucose positron emission tomography in gastric carcinoma:relation to histological subtypes， depth of tumor invasion， and glucose transporter-1 expression［J］. Ann Nucl Med， 2006， 20（9）: 597-604.
|
| ［17］ |
Shimada H， Okazumi S， Koyama M， et al. Japanese Gastric Cancer Association Task Force for Research Promotion: clinical utility of 18F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature［J］. Gastric Cancer， 2011，14（1）: 13-21.
|
| ［18］ |
Zhao L， Pang Y， Luo Z， et al. Role of ［（68） Ga］Ga- DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with ［（18）F］-FDG PET/CT［J］. Eur J Nucl Med Mol Imaging， 2021，48（6）: 1944-1955.
|
| ［19］ |
Zhang H， Dai W， Fu C， et al. Diagnostic value of whole-body MRI with diffusion-weighted sequence for detection of peritoneal metastases in colorectal malignancy［J］. Cancer Biol Med， 2018， 15（2）: 165-170.
|
| ［20］ |
Qin C， Shao F， Gai Y， et al. 68Ga-DOTA-FAPI-04 PET/MR in the evaluation of gastric carcinomas: comparison with 18F-FDG PET/CT［J］. J Nucl Med， 2022， 63（1）: 81-88.
|
| ［21］ |
Mei LJ， Wang LW， Huang CQ， et al. Oral gastrografin radiography for the evaluation of the functional impact of peritoneal carcinomatosis:correlation with clinicopathological findings［J］. Mol Clin Oncol， 2015，3（5）: 979-986.
|
| ［22］ |
Yang XQ， Chen C， Peng CW， et al. Carbohydrate antigen 242 highly consists with carbohydrate antigen 19-9 in diagnosis and prognosis of colorectal cancer: study on 185 cases［J］. Med Oncol， 2012， 29（2）:1030-1036.
|
| ［23］ |
Chen C， Chen LQ， Yang GL， et al. The application of C12 biochip in the diagnosis and monitoring of colorectal cancer: systematic evaluation and suggestion for improvement［J］. J Postgrad Med， 2008，54（3）: 186-190.
|
| ［24］ |
Wagner PL， Austin F， Sathaiah M， et al. Significance of serum tumor marker levels in peritoneal carcinomatosis of appendiceal origin［J］.Ann Surg Oncol， 2013， 20（2）: 506-514.
|
| ［25］ |
Yonemura Y， Canbay E， Li Y， Coccolini F， et al. A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent［J］. Eur J Surg Oncol， 2016， 42（8）: 1123-1131.
|
| ［26］ |
Pelz JO， Stojadinovic A， Nissan A， et al. Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis［J］. J Surg Oncol， 2009， 99（1）: 9-15.
|
| ［27］ |
中国抗癌协会. 中国肿瘤整合诊治指南（第二版）下册［M］. 天津:天津科学技术出版社， 2024: 1671-1673.
|
| ［28］ |
Spratt JS， Adcock RA， Muskovin M， et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy［J］. Cancer Res， 1980，40（2）: 256-260.
|
| ［29］ |
Sugarbaker PH. Peritonectomy procedures［J］. Surg Oncol Clin N Am，2003， 12（3）: 703-727.
|
| ［30］ |
Yonemura Y， Elnemr A， Endou Y， et al. Surgical results of patients with peritoneal carcinomatosis treated with cytoreductive surgery using a new technique named aqua dissection［J］. Gastroenterol Res Pract，2012， 2012: 521487.
|
| ［31］ |
Mizumoto A， Canbay E， Hirano M， et al. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a single institution in Japan［J］. Gastroenterol Res Pract， 2012， 2012: 836425.
|
| ［32］ |
Huang CQ， Yang XJ， Yu Y， et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: a phase II study from a Chinese center［J］. PLoS One， 2014， 9（9）: e108509.
|
| ［33］ |
Sugarbaker PH. Cytoreductive surgery plus hyperthermic perioperative chemotherapy for selected patients with peritoneal metastases from colorectal cancer: a new standard of care or an experimental approach？［J］. Gastroenterol Res Pract， 2012， 2012: 309417.
|
| ［34］ |
Elias D， Mariani A， Cloutier AS， et al. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin［J］. Eur J Surg Oncol， 2014， 40（11）: 1467-1473.
|
| ［35］ |
Glehen O， Kwiatkowski F， Sugarbaker PH， et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study［J］. J Clin Oncol， 2004， 22（16）: 3284-3292.
|
| ［36］ |
Verwaal VJ， van Ruth S， de Bree E， et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer［J］. J Clin Oncol， 2003，21（20）: 3737-3743.
|
| ［37］ |
Verwaal VJ， Bruin S， Boot H， et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer［J］. Ann Surg Oncol， 2008， 15（9）:2426-2432.
|
| ［38］ |
Huang CQ， Feng JP， Yang XJ， et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from colorectal cancer: a casecontrol study from a Chinese center［J］. J Surg Oncol， 2014， 109（7）:730-739.
|
| ［39］ |
Franko J， Ibrahim Z， Gusani NJ， et al. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis［J］.Cancer， 2010， 116（16）: 3756-3762.
|
| ［40］ |
Mirnezami R， Mehta AM， Chandrakumaran K， et al. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone［J］. Br J Cancer， 2014， 111（8）: 1500-1508.
|
| ［41］ |
Taqi K， Lee J， Hurton S， et al. Long-term outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin［J］. Curr Oncol， 2024，31（7）: 3657-3668.
|
| ［42］ |
Kitaguchi D， Park EJ， Baik SH， et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus R0 resection for resectable colorectal cancer with peritoneal metastases and low peritoneal can cerind exscores: a collaborative observational study from Korea and Japan［J］. Int J Surg， 2024， 110（1）: 45-52.
|
| ［43］ |
Sarofim M， Wijayawardana R， Ahmadi N， et al. Neoadjuvant chemotherapy does not improve survival for patients with high volume colorectal peritoneal metastases undergoing cytoreductive surgery［J］.World J Surg Oncol， 2024， 22（1）: 103-109.
|
| ［44］ |
Chen D， Ma Y， Li J， et al. Risk factors for postoperative complications in patients undergoing cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: a meta-analysis and systematic review［J］. Int J Colorectal Dis， 2024， 39（1）: 167-183.
|
| ［45］ |
Dietz MV， Hannink G， Said I， et al. Development of a prediction model for recurrence in patients with colorectal peritoneal metastases undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy［J］. Eur J Surg Oncol， 2024， 50（6）: 108294.
|
| ［46］ |
Tonello M， Cenzi C， Pizzolato E， et al. Systemic chemotherapy in colorectal peritoneal metastases treated with cytoreductive surgery:systematic review and meta-analysis［J］. Cancers （Basel）， 2024， 16（6）:1182-1197.
|
| ［47］ |
Sammartino P， Sibio S， Biacchi D， et al. Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases［J］. Int J Colorectal Dis，2014， 29（9）: 1081-1089.
|
| ［48］ |
Cortes-Guiral D， Elias D， Cascales-Campos PA， et al. Second-look surgery plus hyperthermic intraperitoneal chemotherapy for patients with colorectal cancer at high risk of peritoneal carcinomatosis: Does it really save lives？［J］. World J Gastroenterol， 2017， 23（3）: 377-381.
|
| ［49］ |
Segelman J， Akre O， Gustafsson UO， et al. External validation of models predicting the individual risk of metachronous peritoneal carcinomatosis from colon and rectal cancer［J］. Colorectal Dis， 2016，18（4）: 378-385.
|
| ［50］ |
Baratti D， Kusamura S， Iusco D， et al. Hyperthermic intraperitoneal chemotherapy （HIPEC） at the time of primary curative surgery in patients with colorectal cancer at high risk for metachronous peritoneal metastases［J］. Ann Surg Oncol， 2017， 24（1）: 167-175.
|
| ［51］ |
Zheng Y， Zhang J， Chen C， et al. Prophylactic hyperthermic intraperitoneal chemotherapy in T4 colorectal cancer: Can it improve the oncologic prognosis？ - A propensity score matching study［J］. Eur J Surg Oncol， 2024， 50（2）: 107958.
|
| ［52］ |
Zhou H， Wang H， Yi S， et al. Effectiveness of hyperthermic intraperitoneal chemotherapy during primary curative resection for colorectal carcinoma［J］. Int J Colorectal Dis， 2024，39（1）: 197.
|
| ［53］ |
Sun BJ， Daniel SK， Lee B. The role of prophylactic and adjuvant hyperthermic intraperitoneal chemotherapy （HIPEC） in prevention of peritoneal metastases in advanced colorectal cancer［J］. J Clin Med，2023， 12（20）: 6443.
|
| ［54］ |
Arjona-Sánchez A， Espinosa-Redondo E， Gutiérrez-Calvo A， et al.Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colon cancer: a phase 3 randomized clinical trial［J］. JAMA Surg， 2023， 158（7）: 683-691.
|